Search by Drug Name or NDC
NDC 47918-0903-27 AFREZZA Details
AFREZZA
AFREZZA is a RESPIRATORY (INHALATION) KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Mannkind Corporation. The primary component is .
MedlinePlus Drug Summary
Insulin inhalation is used in combination with a long-acting insulin to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used in combination with other medications to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood) who need insulin to control their diabetes. Insulin inhalation is not used for the treatment diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). Insulin inhalation is a short-acting, man-made version of human insulin. Insulin inhalation works by replacing the insulin that is normally produced by the body and by helping to move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 47918-0903-27Last Updated: 04/14/2024
MedLinePlus Full Drug Details: Insulin Human Inhalation
Product Information
NDC | 47918-0903 |
---|---|
Product ID | 47918-903_590032d0-a528-4d1e-ad37-bd33398f1fe8 |
Associated GPIs | |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | AFREZZA |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | INSULIN HUMAN |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | KIT |
Route | RESPIRATORY (INHALATION) |
Active Ingredient Strength | n/a |
Active Ingredient Units | n/a |
Substance Name | n/a |
Labeler Name | Mannkind Corporation |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA022472 |
Listing Certified Through | 2024-12-31 |
Package
NDC 47918-0903-27 (47918090327)
NDC Package Code | 47918-903-27 |
---|---|
Billing NDC | 47918090327 |
Package | 1 KIT in 1 CARTON (47918-903-27) * 2 BLISTER PACK in 1 NOT APPLICABLE / 9 CARTRIDGE in 1 BLISTER PACK / 1 POWDER, METERED in 1 CARTRIDGE * 2 BLISTER PACK in 1 NOT APPLICABLE / 9 CARTRIDGE in 1 BLISTER PACK / 1 POWDER, METERED in 1 CARTRIDGE * 2 BLISTE |
Marketing Start Date | 2020-11-09 |
NDC Exclude Flag | N |
Pricing Information | N/A |